Medicinal cannabis approvals in Australian children and young people, 2016–2024: a national analysis of Therapeutic Goods Administration data by age, indication and cannabinoid category
4 affiliations
- 1General Practice and Primary Care, Faculty of Medicine Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia
- 2Department of Addiction Medicine, St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia
- 3Department of Mental Health, The Royal Children’s Hospital Melbourne Mental Health Service, Parkville, Victoria, Australia
- 4Department of Medicine, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia
Abstract
Objective: To describe patterns of Special Access Scheme Category B (SAS-B) medicinal cannabis approvals among children and young people aged 25 years or younger in Australia using national regulatory data.
Design: National descriptive analysis of Therapeutic Goods Administration (TGA) SAS-B approvals for medicinal cannabis.
Setting: Australian national regulatory setting, using SAS-B approval data, through which registered medical and nurse practitioners may obtain TGA approval before prescribing unapproved medicinal cannabis products to individual patients.
Participants: Individuals aged 25 years or younger with approved TGA SAS-B applications for medicinal cannabis from February 2016 to May 2024.
Main outcome measures: Number and distribution of medicinal cannabis approvals by age, sex, indication, product category, formulation and practitioner characteristics.
Results: A total of 52 419 approved applications were included. SAS-B approvals increased substantially over time, with a more marked increase observed from 2021. Approvals were concentrated in older adolescents and young adults, with 71% of approvals in those aged 20–25 years. Overall, 62.6% of approvals were for males. Anxiety (43%), chronic pain (28%), neurodevelopmental conditions (10%) and sleep disorders (9%) were the most common indications. Approvals for younger children more commonly involved cannabidiol-dominant products and oil formulations, whereas approvals in older age groups more frequently involved THC-dominant product categories and inhaled formulations. Among approvals with a recorded prescriber specialty, general practice was the most frequently identified specialty.
Conclusions: Medicinal cannabis SAS-B approvals for young people in Australia have expanded substantially and are concentrated in older adolescents and young adults. Approvals are occurring for conditions with limited evidence, with THC product categories predominating among approvals for older adolescents and young adults. These findings highlight the need for improved clinical guidance, age-specific oversight and systematic monitoring of outcomes to support safer, evidence-based use.
Related
- The Therapeutic Effects of 4-Aminopyridine Administration via Phonophoresis on Sutured Postoperative Wounds: A Histopathological, Immunohistochemical, Molecular, and Morphometric Study
- Therapeutic Administration of Malva parviflora Hydroalcoholic Extract Restores Cognitive Function Consistent with a Resilient Phenotype in Female 5XFAD.
- Additive effects of active vitamin D3 or vitamin E administration on therapeutic lower-limb home exercise for knee osteoarthritis: A pilot prospective randomized controlled trial.
- Protective Effects of Prophylactic and Therapeutic Erythromycin Administration in Ovarian Ischemia-Reperfusion Injury in Rats.
- A Critical Review of Cannabinoid Metabolites: From Biotransformation to the Urban Water Cycle and Reported Monitoring
BibTeX
@article{hallinan2026medicinal,
title = {{Medicinal cannabis approvals in Australian children and young people, 2016–2024: a national analysis of Therapeutic Goods Administration data by age, indication and cannabinoid category}},
author = {Christine Mary Hallinan and Hae-Young Connie Chong and Amanda Norman and Yvonne Bonomo},
journal = {BMJ Open},
year = {2026},
month = oct,
doi = {10.1136/bmjopen-2026-121855},
url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-121855},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Medicinal cannabis approvals in Australian children and young people, 2016–2024: a national analysis of Therapeutic Goods Administration data by age, indication and cannabinoid category
AU - Christine Mary Hallinan
AU - Hae-Young Connie Chong
AU - Amanda Norman
AU - Yvonne Bonomo
PY - 2026
DA - 2026/10/25
JO - BMJ Open
DO - 10.1136/bmjopen-2026-121855
UR - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-121855
AB - Objective: To describe patterns of Special Access Scheme Category B (SAS-B) medicinal cannabis approvals among children and young people aged 25 years or younger in Australia using national regulatory data. Design: National descriptive analysis of Therapeutic Goods Administration (TGA) SAS-B approvals for medicinal cannabis. Setting: Australian national regulatory setting, using SAS-B approval data, through which registered medical and nurse practitioners may obtain TGA approval before prescribing unapproved medicinal cannabis products to individual patients. Participants: Individuals aged 25 years or younger with approved TGA SAS-B applications for medicinal cannabis from February 2016 to May 2024. Main outcome measures: Number and distribution of medicinal cannabis approvals by age, sex, indication, product category, formulation and practitioner characteristics. Results: A total of 52 419 approved applications were included. SAS-B approvals increased substantially over time, with a more marked increase observed from 2021. Approvals were concentrated in older adolescents and young adults, with 71% of approvals in those aged 20–25 years. Overall, 62.6% of approvals were for males. Anxiety (43%), chronic pain (28%), neurodevelopmental conditions (10%) and sleep disorders (9%) were the most common indications. Approvals for younger children more commonly involved cannabidiol-dominant products and oil formulations, whereas approvals in older age groups more frequently involved THC-dominant product categories and inhaled formulations. Among approvals with a recorded prescriber specialty, general practice was the most frequently identified specialty. Conclusions: Medicinal cannabis SAS-B approvals for young people in Australia have expanded substantially and are concentrated in older adolescents and young adults. Approvals are occurring for conditions with limited evidence, with THC product categories predominating among approvals for older adolescents and young adults. These findings highlight the need for improved clinical guidance, age-specific oversight and systematic monitoring of outcomes to support safer, evidence-based use.
SN - 2044-6055
SN - 2044-6055
ER -